Breathe Easy progresses to next phase of clinical trials
The cystic fibrosis drug developer raised $2 million earlier this year from angels and crowdfunding - with special audio feature.
Click the NBR Radio box for on-demand special feature audio: Breathe Easy chief executive Andrea Miller on the company's second phase of clinical trials
Biotech company Breathe Easy is launching its second phase of clinical trials for its cystic fibrosis drug, after raising $2 million earlier this
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Wed, 09 Dec 2015
Wed, 09 Dec 2015
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Breathe Easy progresses to next phase of clinical trials
54175